

## SPECIALTY QUANTITY LIMIT PROGRAM

### LEMTRADA (alemtuzumab)

#### I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

#### II. COVERED QUANTITIES

Medication	Standard Limit	FDA-recommended dosing
Lemtrada 12 mg/1.2 mL (10 mg/mL) single-dose vial for infusion	5 vials per 12 months	First course: 12 mg/day on 5 consecutive days  Second course: 12 mg/day on 3 consecutive days 12 months after first treatment course  Subsequent treatment courses of 12 mg/day on 3 consecutive days may be administered, as needed, at least 12 months after the last dose of any prior treatment course

#### III. REFERENCES

1. Lemtrada [package insert]. Cambridge, MA: Genzyme Corporation; January 2019.